Babbage: A flicker of light for Alzheimer’s

After almost two decades, the FDA has granted conditional approval to a drug for the treatment of Alzheimer’ disease, called aducanumab. But the new drug, and its approval, is surrounded by controversy. Will the gamble pay off? Also, a clever upgrade to fog-collecting technology which could provide a water source in remote locations. And, potentially life-saving oxygen enemas? Kenneth Cukier hosts 

For full access to The Economist’s print, digital and audio editions subscribe at and sign up for our new weekly science newsletter at


See for privacy and opt-out information.